Bausch Health Companies (BHC) Expected to Announce Earnings on Wednesday

Bausch Health Companies (NYSE:BHC - Get Free Report) is anticipated to announce its Q1 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of $1.46 per share and revenue of $2.29 billion for the quarter. Bausch Health Companies has set its FY 2025 guidance at EPS.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The business had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Bausch Health Companies Stock Down 1.1 %

Bausch Health Companies stock traded down $0.06 during mid-day trading on Friday, hitting $5.42. The company's stock had a trading volume of 1,345,757 shares, compared to its average volume of 2,705,382. The stock has a market capitalization of $1.99 billion, a P/E ratio of -45.16, a P/E/G ratio of 0.37 and a beta of 0.43. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $9.85. The stock's fifty day moving average price is $6.23 and its two-hundred day moving average price is $7.32.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BHC. Royal Bank of Canada cut their target price on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating on the stock in a research report on Monday, April 7th. StockNews.com downgraded shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, Jefferies Financial Group reiterated a "hold" rating and set a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. According to MarketBeat.com, Bausch Health Companies currently has a consensus rating of "Hold" and a consensus target price of $7.17.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.